Indication
As monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.
Medicine details
- Medicine name:
- cabozantinib (Cabometyx)
- SMC ID:
- SMC2590
- Pharmaceutical company
- Ipsen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 12 February 2024
- SMC meeting date:
- 09 January 2024
- Patient group submission deadline:
- 06 November 2023